Nanomix Corporation announced that it has entered into a distribution agreement with IPS Genomix s.a.l., a medical diagnostics distributor with offices in Beirut, Lebanon and Dubai, UAE. The Nanomix S-1 panel is designed to provide rapid test results for an aid in diagnosing critical infections including Sepsis. Sepsis is a recognized global health crisis.

Early identification and treatment is a need and a challenge for healthcare professionals around the globe. For many reasons, sepsis can be difficult to identify and is frequently under-diagnosed in the earliest stages. It affects as many as 50 million people every year, leading to approximately 11 million deaths annually.

The Nan mix eLab(R) system is a mobile, hand-held immunoassay and chemistry diagnostic system designed for the needs of rapid point-of-care testing. The Nan mix eLab(R) system offers a variety of benefits, including results in minutes, lower cost, and portability, while providing accurate, quantitative results comparable in quality to those provided by central lab testing. The S1 Panel Assay was developed as an aid in rapidly diagnosing critical infections including sepsis.

The panel provides quantitative test results for procalcitonin, C-reactive protein and lactate from a single venous whole blood or plasma sample type. The assay runs on the eLab(R) Analyzer with results available in approximately 12 minutes from sample to answer, versus the current diagnostic solutions which can take hours to provide a test result. The S1 Panel assay has received the CE marking in Europe and has UK Medicines and Healthcare products Regulatory Agency registration.